ReviewCurrent atherosclerosis reports2026
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circulation research · 2026Review
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.Current atherosclerosis reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize key findings from cardiovascular disease prevention trials at the 2025 American Heart Association (AHA) Scientific Sessions. RECENT
findingsIn a phase 2 trial, DR10624, a novel triple agonist, rapidly led to significant reductions in triglycerides and liver fat in patients with severe hypertriglyceridemia (sHTG). The CORE-TIMI 72a and CORE2-TIMI 72b trials showed that olezarsen markedly lowered triglycerides and reduced the risk of acute pancreatitis in patients with severe hypertriglyceridemia. The VESALIUS-CV trial demonstrated that evolocumab significantly lowered first major cardiovascular events in high-risk adults without prior myocardial infarction or stroke. The CORALreef Lipids trial found that the oral Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitor enlicitide reduced low-density lipoprotein cholesterol (LDL-C) by over 55%, with sustained lipid-lowering effects at 52 weeks. The CORALreef HeFH trial confirmed similar LDL-C reductions in patients with heterozygous familial hypercholesterolemia, supporting enlicitide as an effective oral alternative to injectable PCSK9 inhibitors. The BETTER-BP trial demonstrated that a lottery-based behavioral economics incentive model did not result in a significant reduction of SBP at 6 months. The GoFresh trial found that home-delivered DASH-style groceries, combined with brief counseling, significantly improved systolic blood pressure and LDL-C levels among Black adults living in food-insecure urban settings. The Healthy Family Program in rural China showed that a low-cost, family-centered intervention meaningfully reduced systolic and diastolic blood pressure, with benefits persisting after the program ended. The ELM lifestyle trial showed that a long-term behavioral intervention increased sustained remission of metabolic syndrome while improving multiple cardiometabolic behaviors. Finally, the DECAF trial challenged common assumptions by demonstrating that caffeinated coffee consumption reduced recurrence of atrial fibrillation following cardioversion compared with abstinence. Trials presented at the 2025 AHA Scientific Sessions emphasized new therapeutic, behavioral, and community-based strategies for cardiovascular disease risk reduction. These findings underscore a growing shift toward more effective and accessible approaches to improving cardiovascular health.
Indexed as
Identifiers
41493497What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.